- Reference code :
- wf386
- Published date :
-
23 April 2001
- Expired date :
-
08 September 2028
AstraZeneca confirmed today that it has filed a lawsuit in Illinois against Apotex Corporation and Torpharm for patent infringement.
The lawsuit is the result of an Abbreviated New Drug Application (ANDA) filed by Torpharm with the Food and Drug Administration (FDA) concerning its intent to market a generic omeprazole product in the US. The antisecretory drug omeprazole is marketed in the US by AstraZeneca, L.P. under the brand name Prilosec® and is marketed internationally by AstraZeneca as Losec®.
The basis for AstraZeneca's complaint is that the action by Torpharm infringes at a minimum formulation patents for Prilosec® and patents relating to the treatment of H.Pylori infections.
AstraZeneca intends to fully enforce its patent rights and is steadfast in its belief that all the patents are valid.
Further enquires to:
Media RelationsChris Major +44 20 7304 5028 |
Investor RelationsMichael Olsson +44 (0)20 7304 5087 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At Nov 21, 2009 4:47 AM GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
